Lonza Begins Tender Offer To Acquire Arch Chemicals

Biocides company Arch Chemicals announced that Lonza's subsidiary, Lonza LG Acquisition Corp., has commenced the previously announced offer to acquire all of the outstanding shares of common stock of Arch Chemicals at a price of $47.20 per share, net to the seller in cash, without interest and less any required withholding of taxes.

The tender offer is scheduled to expire on Aug. 11. The closing of the tender offer is subject to customary terms and conditions. On July 11, Lonza announced its intention to acquire Arch through a tender offer for $47.20 per share in cash. As per the deal, the germs control product maker's enterprise value would be $1.4 billion or about 1.25 billion Swiss francs.

 

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read